학술논문

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
Document Type
Article
Author
Cahn, PedroMadero, Juan SierraArribas, José RamónAntinori, AndreaOrtiz, RobertoClarke, Amanda EHung, Chien-ChingRockstroh, Jürgen KGirard, Pierre-MarieSievers, JörgMan, ChoyCurrie, AlexanderUnderwood, MarkTenorio, Allan RPappa, KeithWynne, BrianFettiplace, AnnaGartland, MartinAboud, MichaelSmith, KimberlyCassetti, LidiaDavid, DanielFigueras, LauraLosso, MarceloLopardo, GustavoLupo, SergioPorteiro, NormaSánchez, MarisaBloch, MarkCooper, DavidFinlayson, RobertKelleher, AnthonyKoh, KennethLewis, DavidMcMahon, JamesMoore, RichardRoth, NormanShields, MatthewDe Wit, StephaneFlorence, EricGoffard, Jean-ChristopheDemeester, RemyLacor, PatrickVandercam, BernardVandekerckhove, LinosAngel, JonathanBaril, Jean-GuyConway, BrianDe Pokomandy, AlexandraSzabo, JasonWalmsley, SharonBouchaud, OlivierChidiac, ChristianDelobel, PierreGoujard, CecileKatlama, ChristineMolina, Jean-MichelPialoux, GillesPhilibert, PatrickBogner, JohannesEsser, StefanKrznaric, IvankaLehmann, ClaraSpinner, ChristophStellbrink, Hans-JurgenStephan, ChristophStoehr, AlbrechtBarchi, EnricoCaramello, PietroCastelli, FrancescoCattelan, Anna MariaD'Arminio Monforte, AntonellaDi Biagio, AntonioDi Perri, GiovanniGori, AndreaMaggiolo, FrancoMenzaghi, BarbaraMigliorino, GuglielmoMussini, CristinaPenco, GiovanniPuoti, MassimoRizzardini, GiulianoGulminetti, RobertoLazzarin, AdrianoQuirino, TizianoSighinolfi, LauraViale, PierluigiAmaya Tapia, GerardoAndrade Villanueva, JaimeGranados Reyes, Enrique RPerez Rios, AlmaSantoscoy Gomez, MarioDen Hollander, JanRijnders, BartHidalgo, José AHercilla Vasquez, LuisIllescas, LuisOlczak, AnitaMansinho, KamalCorreia Pacheco, Patricia PaulaTeófilo, EugénioSaraiva da Cunha, JoseSarmento e Castro, RuiSerrão, RosárioArbune, ManuelaJianu, CristianOprea, AncaPreotescu, LilianaPrisacariu, Liviu-JanyBelonosova, ElenaBorodkina, OlgaChernova, OxanaGankina, NataliaKizhlo, SvetlanaKulagin, ValeriyKurina, NadezhdaNagimova, FirayaPokrovsky, VadimRyamova, ElenaVoronin, EvgenyYakovlev, AlexeyKaplan, RichardLee, Sun HeeKim, Shin-WooKim, Sang-IlKim, Woo JooAntela Lopez, AntonioCasado Osorio, Jose LCastaño Carracedo, Manuel ADe Los Santos Gil, IgnacioEstrada Perez, VicenteFalco Ferrer, VicençForce, LuisGalinda Puerto, Maria JoseGarcia Deltoro, MiguelGatell, Josep MGoenaga Sanchez, Miguel AGonzález Cordón, AnaKnobel, HernandoLopez Bernaldo de Quiros, Juan CarlosLosa Garcia, Juan EMasia, MarMontero-Alsonso, MartaOcampo Hermida, AntonioPasquau Liaño, JuanPortilla Sogorb, JoaquinPulido Ortega, FedericoRivera Roman, AntonioSantos Fernandez, Jose RamonTorres Perea, RafaelTroya Garcia, JesusViciana Fernandez, PompeyoCalmy, AlexandraHauser, ChristophFehr, JanCheng, Shu-HsingKo, Wen-ChienLin, Hsi-HsunLu, Po-LiangTseng, Yu-TingWang, Ning-ChiWong, Wing-WaiYang, Chia-JuiArduino, RobertoBenson, PaulBerhe, MezgebeBredeek, FritzBrinson, CynthiaCampbell, ThomasCrofoot, GordonCunningham, DouglasDeJesus, EdwinDretler, RobinEron, JosephFife, KennethFichtenbaum, CarlFlamm, JasonGoldstein, DeborahGupta, SamirHagins, DebbieHoffman-Terry, MargaretJayaweera, DushyanthaKinder, CliffordKlein, DanielMcDonald, CherylMills, AnthonyNahass, RonaldOsiyemi, OlayemiOverton, EdgarParks, DavidPrelutsky, DavidRamgopal, MotiSchrader, ShannonSha, BeverlySimon, GarySims, JamesSkiest, DanielSlim, JihadTashima, KarenThedinger, BlairGazzard, BrianFox, JulieJohnson, MargaretKegg, StephenKhoo, SayeMazhude, CharlesOrkin, ChloeSchembri, GabrielUstianowski, Andrew
Source
The Lancet; January 2019, Vol. 393 Issue: 10167 p143-155, 13p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared with a three-drug regimen for the treatment of HIV-1 infection in ART-naive adults.